Cefpodoxime 50 mg + Clavulanic Acid 31.25mg With Water
Cefpodoxime (50mg/5mL) + Clavulanic Acid (31.25mg/5mL) paediatric suspension. Cefpodoxime provides third-generation cephalosporin coverage with MSSA activity. Clavulanic acid irreversibly inhibits beta-lactamase enzymes produced by resistant organisms, extending cefpodoxime's spectrum to include beta-lactamase-producing H. influenzae, M. catarrhalis, and S. aureus strains that would otherwise inactivate the cefpodoxime. This combination is the paediatric suspension equivalent of adult co-amoxiclav but with the superior gram-negative spectrum of a third-generation cephalosporin.
Moderate-to-severe paediatric ENT infections with suspected resistant organisms: recurrent or severe acute otitis media, complicated sinusitis, tonsillitis unresponsive to first-line therapy. Also indicated for community-acquired pneumonia, complicated UTIs, and skin infections where beta-lactamase-producing strains are implicated. Standard dose range: children 8–20 kg.
Dosage and administration should be as prescribed by a qualified doctor or medical professional. Do not self-medicate. Always follow your physician's instructions regarding dose, frequency and duration of treatment.
PODROCK™ CV fills the clinical gap for paediatric patients who have failed first-line cephalosporin therapy and where resistant beta-lactamase-producing organisms are suspected. Its position as a step-up within the PODROCK™ brand allows prescribers to escalate within a familiar, trusted product family rather than switching to an entirely new brand.
Disclaimer: To be used under medical supervision only. Not intended for general public promotion. This content is meant for registered healthcare professionals only.